Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 230

Results For "IMA"

3214 News Found

USFDA clears Franklin Mountain Medical's new dual catheter
Biotech | April 26, 2022

USFDA clears Franklin Mountain Medical's new dual catheter

It enables precise visualization and treatment access to the left heart


GSK launches once daily, single inhaler-triple therapy for COPD patients
Drug Approval | April 26, 2022

GSK launches once daily, single inhaler-triple therapy for COPD patients

Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers


Corbevax gets DCGI nod for Emergency Use in 5-12 years
Drug Approval | April 26, 2022

Corbevax gets DCGI nod for Emergency Use in 5-12 years

The approval comes soon after Corbevax was given the nod for 12-15-year group


DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Drug Approval | April 26, 2022

DCGI grants Covaxin Emergency Use Approval for children 6-12 years

Covaxin was earlier approved for children 12-18 years of age


Aleor Dermaceuticals receives USFDA approval for Clobestasol
Drug Approval | April 25, 2022

Aleor Dermaceuticals receives USFDA approval for Clobestasol

Clobetasol Propionate Foam, 0.05% has an estimated market size of US $ IO million for twelve months ending Dec 2021 according to IQVIA


Shionogi’s once-a-day Covid-19 anti-viral shows rapid virus clearance
Biotech | April 25, 2022

Shionogi’s once-a-day Covid-19 anti-viral shows rapid virus clearance

A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year


‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
Biotech | April 25, 2022

‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology

Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia


Glenmark is the first to launch Teneligliptin and Pioglitazone Fixed-Dose Combination
News | April 25, 2022

Glenmark is the first to launch Teneligliptin and Pioglitazone Fixed-Dose Combination

The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.


Glamyo Health records ARR of US $ 8 million last fiscal
Startup | April 25, 2022

Glamyo Health records ARR of US $ 8 million last fiscal

It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care


GOQii to foray into UK patient care with GBP 10 million investment
Startup | April 25, 2022

GOQii to foray into UK patient care with GBP 10 million investment

Partnership with Modality, award-winning GP super partnership